<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470284</url>
  </required_header>
  <id_info>
    <org_study_id>SMART-BP</org_study_id>
    <nct_id>NCT04470284</nct_id>
  </id_info>
  <brief_title>Mobile App for BP Control</brief_title>
  <acronym>SMART-BP</acronym>
  <official_title>Self-Monitoring of and Feed-back Using APP. in TReatment of UnconTroled Blood Pressure (SMART-BP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SMART-BP is a randomized, controlled study in which hypertensive patients are allocated to&#xD;
      self monitoring of blood pressure monitoring (SMBP) only group or SMBP with mobile App based&#xD;
      feed-back algorithm (SMBP-App) group. The App based feed-back algorithm will provide the&#xD;
      patients with instruction in response to the measured BP value, e.g. remind of taking drug,&#xD;
      if high blood pressure is detected.&#xD;
&#xD;
      The primary outcomes are mean systolic BP change and drug compliance at 12-weeks. Secondary&#xD;
      endpoints include mean diastolic BP change at 12-week, mean systolic and diastolic BP change&#xD;
      at 12 and 24 weeks, and drug compliance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a prospective, randomized, open-label, multicenter trial to evaluate the&#xD;
      efficacy of SMBP with mobile health application (SMBP-App) compared with SMBP alone.&#xD;
&#xD;
      Patients with hypertension will be randomly assigned to SMBP-App (intervention) and SMBP&#xD;
      along (control) groups. In SMBP group the patients perform home blood pressure measurement&#xD;
      and usual care. In SMBP-App group the patients perform home blood pressure and receive extra&#xD;
      alarm and instructions from the mobile application in response to the obtained blood pressure&#xD;
      value.&#xD;
&#xD;
      The aim of this study is to evaluate whether SMBP-App is superior to SMBP alone in terms of&#xD;
      blood pressure reduction and improved drug compliance in patients with hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>mean systolic blood pressure change from baseline to 12 weeks [in mmHg]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Drug compliance using pill count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic BP</measure>
    <time_frame>12 weeks</time_frame>
    <description>mean sitting diastolic BP change from baseline to 12 weeks in mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>SMBP_only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment with SMBP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMBP_mobile_app</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMBP with mobile App based feed-back algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mobile Application</intervention_name>
    <description>SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.</description>
    <arm_group_label>SMBP_mobile_app</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard SMBP</intervention_name>
    <description>Standard treatment</description>
    <arm_group_label>SMBP_only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients with essential hypertension, aged 19 years or older&#xD;
&#xD;
          -  Sitting SBP &gt; 140 mmHg or sitting DBP &gt; 90 mmHg which is confirmed by triplicate&#xD;
             measurements at visit 1&#xD;
&#xD;
          -  Patients able to use smart phone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of secondary hypertension and suspected secondary&#xD;
             hypertension, including coarctation of the aorta, primary hyperaldosteronism, renal&#xD;
             artery stenosis, Cushing's syndrome, pheochromocytoma, and polycystic kidney disease.&#xD;
&#xD;
          -  Patients with a mean systolic BP (SBP) ≥ 200 mmHg or DBP ≥ 110 mmHg at the screening&#xD;
             visit.&#xD;
&#xD;
          -  Patients with uncontrolled diabetes (HbA1c ≥ 9.0%).&#xD;
&#xD;
          -  Patients who have been continuously taking other medicines, such as systemic steroids,&#xD;
             thyroid hormones, oral contraceptives (except for menopausal hormone replacement&#xD;
             therapy), psychiatric drugs, NSAIDs, sympathetic drugs, and immune suppressants, which&#xD;
             have the potential to affect BP.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Ju Choi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National Univeristy Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Ju Choi, MD, PhD</last_name>
    <phone>+82317877007</phone>
    <email>djchoi@snubh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin Joo Park, MD, PhD</last_name>
    <phone>+82317877074</phone>
    <email>jinjooparkmd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea Univ. Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eung-ju Kim, MD,PhD</last_name>
      <phone>82-8-2626-3022</phone>
      <email>withnoel@empas.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Ju Choi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

